CSL 111

Drug Profile

CSL 111

Alternative Names: CSL-111; CSL111 (reconstituted HDL) - CSL

Latest Information Update: 08 Jun 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator CSL
  • Class Cardiovascular therapies; Lipoproteins
  • Mechanism of Action Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acute coronary syndromes; Stroke

Most Recent Events

  • 26 Mar 2007 Results from a phase II clinical trial (ERASE) in patients with Acute Coronary Syndrome added to the adverse events and Ischaemic Heart Disease therapeutic trials sections ,
  • 22 Nov 2006 Preclinical trials in Acute coronary syndromes in Europe (unspecified route)
  • 14 Nov 2006 Preclinical trials in Acute coronary syndromes in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top